Mizuho Securities analyst, Irina Koffler, reiterated her Underperform rating on shares of Valeant Pharmaceuticals (NYSE: VRX) after the company announced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE